Microbot Medical Inc. (MBOT) Company Overview

What does Microbot Medical do?

Microbot Medical Inc. is a commercial-stage medical-device company listed on the Nasdaq Capital Market under the ticker MBOT. Its central product is the LIBERTY Endovascular Robotic System, a single-use, remotely operated platform designed to help physicians navigate guidewires, microcatheters, and related devices during peripheral endovascular procedures. The company describes LIBERTY as the first FDA-cleared single-use remotely operated robotic system for this use, placing Microbot in a narrow but strategically important corner of vascular robotics. The official investor-relations profile frames the business around precision, workflow efficiency, and reducing the physical burden of procedure-room work.

Why does the product matter?

Traditional endovascular procedures require the operator to stand near fluoroscopy equipment while manually manipulating devices. LIBERTY moves device control to a remote workstation and uses a disposable architecture rather than a large reusable capital robot. That design aims to lower the installation burden, reduce maintenance complexity, support rapid setup, and potentially broaden robotic access beyond the largest hospital systems. The system’s commercial proposition therefore depends on more than clinical dexterity: Microbot must show that single-use economics, ease of adoption, and procedure-room workflow justify switching from manual practice or competing robotic platforms.

How does Microbot Medical make money?

Microbot’s business model is built around selling LIBERTY systems and the disposable components required for procedures. The commercial logic resembles a razor-and-blade model, but with a distinctive twist: the robotic system itself is designed to be single-use rather than a large reusable installed base. Revenue therefore should be driven by the number of customer sites, procedure utilization at each site, selling price per system or procedure kit, distributor economics, and manufacturing yield. During the quarter ended March 31, 2026, all reported revenue came from LIBERTY sales to hospital customers participating in the limited market release, according to the company’s first-quarter 2026 Form 10-Q.

Which revenue driver matters most?

At this stage, utilization matters more than nominal market size. A hospital order proves initial interest, but repeat procedures demonstrate clinical acceptance and recurring economic value. Microbot reported only $105,000 of revenue in the first quarter of 2026, so a small number of orders can materially change growth percentages. The company’s July 7, 2026 update said second-quarter revenue and new customers each grew by more than 100% from the first quarter and that procedure volume also rose. The update is encouraging, but investors still need exact second-quarter financial statements before judging gross-margin trajectory, receivable quality, and cash conversion.

What is the principal economic tension?

The tension is between disposable simplicity and early manufacturing cost. Q1 2026 cost of revenue was $103,000 against $105,000 of sales, leaving only $2,000 of gross profit. That approximately 1.9% gross margin is not a mature-unit-economics signal because volumes were tiny and launch costs were high. Nevertheless, it shows that commercialization success requires both demand growth and a meaningful reduction in per-unit production, freight, packaging, and support costs.

What did Microbot Medical’s latest reported quarter show?

The quarter ended March 31, 2026 was Microbot’s first reported period with commercial revenue. The financial statements show a company crossing from development into launch while still spending heavily on sales infrastructure, manufacturing inventory, and corporate operations. Revenue was modest, but balance-sheet liquidity remained substantial because of equity capital raised during 2025.

Why did operating cash burn rise?

Net cash used in operating activities was $5.053 million in Q1 2026, compared with $2.874 million in Q1 2025. Inventory increased by $1.673 million during the quarter, accounts receivable rose by $105,000, and commercialization spending increased. Purchases of property and equipment were $108,000. A simple launch-period free-cash-flow proxy—operating cash flow minus equipment purchases—was therefore approximately negative $5.161 million for the quarter.

How strong is Microbot Medical’s balance sheet?

Liquidity is currently the strongest part of Microbot’s financial profile. At March 31, 2026, cash and cash equivalents were $3.657 million and marketable securities were $68.843 million, for combined cash and marketable securities of $72.500 million. Total current assets were $76.528 million, current liabilities were approximately $3.404 million, and management reported net working capital of about $73.1 million. The company stated that available funds were sufficient for operations for more than one year from the filing date.

Why is liquidity not the same as financial strength?

The cash cushion came primarily from equity issuance, not internally generated cash. Since inception through March 31, 2026, Microbot had raised approximately $168.3 million and accumulated a deficit of about $107.8 million. At the end of 2025, cash and marketable securities totaled $78.592 million, compared with $5.470 million a year earlier, reflecting major financing activity. The 2025 Form 10-K also disclosed 67,158,044 shares outstanding at year-end, versus 19,399,513 at December 31, 2024, illustrating the dilution required to fund development and commercialization.

What should researchers calculate?

At the Q1 2026 operating-cash-use rate of $5.053 million per quarter, the March 31 liquidity balance represented more than three years of purely mechanical runway. That is not a forecast: commercialization may require higher inventory, sales hiring, international submissions, working capital, and post-market support. The better analytical approach is to track cash burn per quarter alongside revenue growth and gross margin. Runway improves only when new revenue begins offsetting the expanding commercial cost base.

Which strategic turning points created today’s Microbot Medical?

Microbot’s current identity is the product of a long transition from preclinical microrobotics to a focused commercial vascular-robotics company. The milestones matter because they explain why the company has a single-product concentration, a large accumulated deficit, and a potentially valuable first-mover position in disposable endovascular robotics.

1. 2010
   Microbot Medical Ltd. was founded in Israel, establishing the microrobotics research base that later became the operating subsidiary.
2. 2016
   A merger with the public company then known as StemCells created the current Nasdaq-listed structure and made Microbot Israel a wholly owned subsidiary.
3. 2020–2023
   The company increasingly concentrated resources on LIBERTY, regulatory preparation, intellectual property, and preclinical validation rather than a broad portfolio.
4. 2024
   Microbot completed its pivotal human clinical study and submitted a 510(k) application in December, converting technical development into a defined regulatory pathway.
5. September 2025
   FDA clearance allowed inventory capitalization, customer deployment, and the move from development accounting to commercial cost-of-revenue accounting.
6. Q3 2025
   The limited market release began in selected high-procedure-volume regions, emphasizing controlled training and early clinical feedback.
7. April 2026
   The full U.S. market release expanded the commercial test from selected centers to a broader customer-acquisition effort.
8. May–July 2026
   Israel granted the first international marketing approval, while the company reported more than 100% sequential growth in Q2 revenue and new customers.

What did FDA clearance change financially?

Before clearance, manufacturing work associated with LIBERTY was generally expensed through R&D. After clearance, units intended for sale were carried in inventory and flowed through cost of revenue when sold. This accounting change is economically important: falling R&D expense does not necessarily mean less technical work, and rising inventory can consume cash before revenue is recognized. The company’s January 2026 milestone update emphasized clearance, commercial preparation, and customer momentum as the bridge into the launch phase.

What gives LIBERTY a competitive advantage?

Microbot’s proposed advantage is not scale; it is product architecture. LIBERTY is designed as a compact, single-use, remotely operated system that can be incorporated into existing endovascular workflows without the footprint and maintenance model of a conventional reusable capital robot. If hospitals perceive the platform as easier to acquire, train on, and deploy, the disposable design could reduce adoption friction. Remote operation also allows physicians to work seated and farther from the radiation source, an occupational benefit that may become more relevant as medical societies emphasize radiation and orthopedic exposure.

Who are the main competitors?

The 2025 Form 10-K identifies CorPath GRX, developed by Corindus Vascular Robotics and owned by Siemens Healthineers, as the main competitor. It also cites Robocath’s R-One+ and notes that other endovascular robotic systems are in development. CorPath benefits from the resources and commercial reach of a global medical-technology company, while Robocath has approvals in several non-U.S. markets. Microbot therefore competes against larger organizations, manual catheter techniques, hospital capital-budget constraints, and physician reluctance to change established practice.

Which KPIs best explain commercialization progress?

For an early commercial medical-device company, conventional revenue growth can be misleading because the starting base is tiny. Microbot’s most decision-useful indicators are customer additions, repeat procedures, units shipped, revenue per site, gross margin, inventory turnover, operating cash burn, and the pace of international approvals. The July 2026 company update reported more than 100% sequential growth in both second-quarter revenue and new customers, but did not provide exact dollar figures. That makes the forthcoming full quarterly report important.

How should gross margin be interpreted?

The 1.9% margin should not be annualized as a steady-state assumption. Initial production runs, low order volume, training support, packaging, freight, and inventory adjustments can distort early results. The relevant trend is whether gross profit per procedure improves as volume rises. A credible commercialization path would combine sequential revenue growth with higher gross margin and slower growth in selling expense per new customer.

What did the latest operating update add?

The company’s July 7, 2026 commercial update said Q2 revenue and new customers each increased by more than 100% from Q1 and that procedure volume rose across multiple sales territories. Because the release supplied growth rates rather than complete financial statements, it confirms momentum but not profitability. Researchers should wait for reported revenue, cost of revenue, receivables, inventory, and operating cash flow before concluding that unit economics improved.

Who owns Microbot Medical stock, and how is it governed?

Microbot has one class of common stock with one vote per share, so it is not a dual-class controlled company. However, the ownership profile reflects a small-cap issuer that has repeatedly used warrants and equity offerings. As of March 24, 2026, the company used 67,158,044 outstanding shares as the base for beneficial-ownership calculations. The 2025 Form 10-K incorporated current ownership disclosure because the company had not yet filed a separate 2026 proxy statement.

What does the board structure signal?

Harel Gadot serves as president, chief executive officer, and chairman, concentrating operational leadership and board agenda-setting in one person. The board includes independent directors, and the 2025 proxy described independent audit, compensation, and corporate-governance committees. The audit committee held five meetings during 2024, the compensation committee four meetings plus one unanimous written consent, and the governance committee three meetings. The 2025 proxy statement is useful for understanding committee composition and executive incentives, while the 2025 Form 10-K provides the more current beneficial-ownership table.

What opportunities could expand Microbot Medical’s addressable market?

The first opportunity is deeper U.S. hospital adoption. Microbot moved from a limited release to a full market release in April 2026, so each additional customer and trained physician can create recurring procedure demand. The second opportunity is international expansion. In May 2026, Israel’s Ministry of Health granted marketing approval, the first clearance outside the United States. The company said this could support a Free Sale Certificate and additional submissions. The official international approval announcement marks the beginning of geographic diversification rather than proof of international revenue.

Can occupational safety become a demand catalyst?

Remote operation may help reduce radiation exposure and the orthopedic burden associated with lead garments and prolonged standing. These benefits can be meaningful for clinicians and hospital safety programs, but they must translate into purchasing decisions. The strongest evidence would be lower operator exposure, efficient setup, high technical success, and repeat physician use. Microbot’s commercial message is strengthened when external medical-society guidance emphasizes occupational protection, although the company still must prove workflow and economic benefits at each site.

Could the platform extend beyond its initial indication?

The company continues to evaluate additional uses, technologies, and partnerships. A platform strategy could eventually support new endovascular indications, integrations, or distribution relationships, but each extension may require development, testing, regulatory submissions, and additional capital. Partnerships with larger medical-device companies could accelerate reach, while licensing or acquisitions could broaden intellectual property. The opportunity is real, but near-term valuation should remain anchored to execution in the cleared peripheral endovascular indication.

What risks could weaken Microbot Medical’s outlook?

Microbot remains a high-execution-risk medical-device company despite regulatory clearance. The largest risk is commercial adoption: hospitals may prefer manual techniques, delay procurement, limit robotic use to a small number of cases, or choose products backed by larger vendors. The second risk is manufacturing. LIBERTY depends on third-party contract manufacturing, component quality, sterilization, packaging, logistics, and inventory management. Low production volumes can keep unit costs high, while defects or recalls could interrupt sales and damage clinician confidence.

Why is dilution a continuing risk?

Microbot has financed operations through common stock, warrants, at-the-market sales, grants, and earlier convertible debt. The share count more than tripled from year-end 2024 to year-end 2025. Although the current liquidity balance reduces immediate financing pressure, commercialization setbacks or higher-than-expected spending could lead to additional issuance. Per-share value therefore depends on both enterprise progress and the number of shares required to finance that progress.

What regulatory and product risks remain after clearance?

FDA clearance permits marketing but does not eliminate post-market obligations, quality-system requirements, complaint handling, reporting, or the possibility of new restrictions. International commercialization requires jurisdiction-specific approvals and distributor execution. Intellectual-property claims can also be challenged or designed around. The most relevant official risk discussion remains the 2025 annual report risk factors, which emphasize dependence on LIBERTY, uncertainty of significant revenue, competition, capital needs, manufacturing, regulation, and intellectual property.

Why does Microbot Medical matter for valuation?

Microbot cannot be valued like a mature medical-device manufacturer because its current revenue is too small, margins are not established, and cash flow is negative. A conventional discounted-cash-flow model requires explicit assumptions about hospital adoption, procedure utilization, price per procedure, gross margin, sales-support intensity, R&D needs, working capital, and dilution. Small changes in those assumptions can produce very large changes in estimated value.

Which scenario variables have the greatest sensitivity?

The most sensitive variables are procedures per site and gross profit per procedure. Customer count alone can overstate progress if installed systems are rarely used. Conversely, modest customer growth can still create attractive economics if sites perform frequent procedures and disposable contribution margins improve. A credible model should separately forecast customer additions, average quarterly procedures per customer, average selling price, cost per procedure, commercial headcount, and inventory investment.

The donut makes the launch-stage challenge visible: nearly all Q1 revenue was absorbed by reported cost of revenue. For valuation, the key question is not whether Q2 revenue doubled from a tiny base, but whether future cohorts of customers create enough recurring gross profit to cover sales, R&D, quality, and public-company costs.

What should students and investors monitor next?

Microbot’s next phase is measurable. The company has regulatory clearance, commercial inventory, a full U.S. release, an initial international approval, and substantial liquidity. The remaining question is whether these assets produce a repeatable operating model. The following indicators should be read together rather than in isolation.

What is the key analytical takeaway?